Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000007)
SBP Name
Affibody Izokibep
Synonyms
ABY-035; ABY035; IMG-020
Molecular Weight 18 kDa
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase II
Protein Scaffold Information of This SBP
Scaffold ID PS004
Scaffold Info
[1]
Scaffold Name Affibody
Scaffold Class Non-Antibody
Fold Type Three Alpha-Helices
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Interleukin-17A
BTS Info
Binder Psoriasis [ICD-11: EA90] Kd: 0.0003 nM Affibody AB [1]
Clinical Trial Information of This SBP
EUCTR2017-001615-36-DE Click to show the Detail
Indication Moderate-to-Severe Plaque Psoriasis
Phase Phase II
Title A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-to-severe plaque psoriasis-AFFIRM-35 Study
Status Authorised
Sponsor Affibody
EUCTR2019-003405-94-ES Click to show the Detail
Indication Active Psoriatic Arthritis (PsA)
Phase Phase II
Title A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035
Status Authorised
Sponsor Affibody
EUCTR2019-003405-94-HU Click to show the Detail
Indication Active Psoriatic Arthritis (PsA)
Phase Phase II
Title A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035
Status Authorised
Sponsor Affibody
NCT02690142 Click to show the Detail
Indication Psoriasis
Phase Phase I
Title A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of?ABY-035?in Healthy Subjects and Psoriasis Patients
Status Completed
Sponsor Affibody
NCT03580278 Click to show the Detail
Indication Psoriasis
Phase Phase I
Title A Safety, Tolerability, Pharmacokinetic, and Efficacy Study of?ABY-035/AFO2 Given as Multiple Doses in Sequential Escalating Dose Cohorts in Psoriasis Subjects
Status Recruiting
Sponsor Affibody
NCT03591887 Click to show the Detail
Indication Moderate-to-Severe Plaque Psoriasis
Phase Phase II
Title A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of?ABY-035?in Subjects With Moderate-to-severe Plaque Psoriasis
Status Active, not recruiting
Sponsor Affibody
NCT04706741 Click to show the Detail
Indication Uveitis
Phase Phase II
Title A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
Status Completed
Sponsor ACELYRIN Inc.
NCT04713072 Click to show the Detail
Indication Psoriatic Arthritis
Phase Phase II
Title A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
Status Completed
Sponsor ACELYRIN Inc.
NCT04795141 Click to show the Detail
Indication Ankylosing Spondylitis
Phase Phase II
Title ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Status Terminated
Sponsor Inmagene LLC
References
1 AffibodyAB. Product Development Pipeline. 2021.